Evidence map›Paper›PMID 33610137›Full record

ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2021

Symptom Burden and Medication Use Among Patients with Nontuberculous Mycobacterial Lung Disease.

Vira Pravosud, David M Mannino, Delia Prieto, Quan Zhang, Radmila Choate, Elisha Malanga, Timothy R Aksamit

Open access · diamondAbstract read
In one paragraph

Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Vira PravosudCollege of Public Health, University of Kentucky, Lexington, Kentucky, United States.
David M ManninoCollege of Public Health, University of Kentucky, Lexington, Kentucky, United States.
Delia PrietoCOPD Foundation, Washington, DC, United States.
Quan ZhangSchool of Public Health, Rutgers University, Piscataway, New Jersey, United States.
Radmila ChoateCollege of Public Health, University of Kentucky, Lexington, Kentucky, United States.
Elisha MalangaCOPD Foundation, Washington, DC, United States.
Timothy R AksamitPulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, United States.
University of Kentucky · USCOPD Foundation · USRutgers, The State University of New Jersey · US

Funding

Insmed
6 · The paper itself

Abstract

purposeRespiratory diseases caused by nontuberculous mycobacteria (NTM) have become a significant concern for patients and health care providers. We aimed to compare symptoms experienced during the 2 week period, at a single point in time, by patients with NTM lung disease (NTMLD) who were currently on any medication to treat their NTMLD versus those not on any therapies.

methodsWe analyzed responses to a "Burden of NTM Survey" developed by the COPD Foundation. The study population included 266 individuals with NTMLD. Using adjusted penalized logistic regression models, we determined associations between the self-reported symptoms and the use of any medication to treat NTMLD.

resultsBased on available data, most respondents were aged 50 and older (95.1%), of female gender (93.1%), and had been living with NTMLD for more than 5 years (55.7%). Many respondents reported symptoms that bother them very often or daily. After adjustment for age and gender, duration of living with NTMLD, and other respiratory illnesses, patients on medication had significantly larger odds of reporting difficulty in walking 500 meters without stopping, difficulty in interacting with others, fatigue or lack of energy, feelings of sadness or depression related to illness, and shortness of breath, wheezing or other difficulties.

conclusionIn this study, patients currently on any medication to treat their NTMLD reported more symptoms associated with their NTMLD. Further investigations are needed to explore whether increased symptoms are related to differences in disease severity and/or medication effects.

Indexed as

BronchandNTM360socialBurden of NTM Surveynontuberculous mycobacterianontuberculous mycobacterial lung diseaseNTMNTMLD

Identifiers

PMID33610137
PMCPMC8237979
OpenAlexW3132721689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.